UCB (ENXTBR:UCB) Could Be 23% Undervalued After Raised 2026 Guidance

UCB (ENXTBR:UCB) is back in focus after first half 2026 results showed sales of €4.09b and net income of €1.11b, with management also raising full year guidance on the back of BIMZELX momentum.

See our latest analysis for UCB.

Despite the strong first half update, UCB’s 1 month share price return is down 13.57% and the 7 day share price return is down 9.39%. However, the 1 year total shareholder return is 21.12% and the 3 year total shareholder return is very large, which points to longer term momentum still in place.

If this kind of earnings driven move has you thinking about where else growth stories could come from, it might be worth scanning 128 healthcare AI stocks

The recent pullback leaves UCB trading well below both analyst targets and some intrinsic value estimates. Does that gap point to mispricing after strong earnings, or indicate a fair reset ahead of the next phase of execution?

Most Popular Narrative: 23% Undervalued

Analysts estimate UCB’s fair value at around €288 per share compared with the last close at €222.90. This frames the recent pullback against a higher long-term narrative.

UCB's deep and advancing innovation pipeline, along with its focus on differentiated products in neurology and immunology, supports the ability to launch multiple new indications, address rare/orphan diseases, and leverage advances in personalized medicine, all of which underpin sustained long-term revenue growth and margin expansion.

Read the complete narrative.

Curious what revenue path and margin profile sit behind that fair value? The narrative leans on steady expansion, a richer mix, and a future earnings multiple that many investors would usually associate with fast-growing compounders.

Result: Fair Value of €288.21 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, UCB’s story could look very different if pricing pressure on BIMZELX intensifies, or if key neurology and immunology pipeline assets face clinical or reimbursement setbacks.

Find out about the key risks to this UCB narrative.

Next Steps

If this UCB update has you weighing the balance of optimism and caution, it makes sense to act quickly and test the story against the numbers yourself. To see both the potential upsides and the key issues that other investors are watching, take a closer look at the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond UCB?

If UCB has sharpened your focus on where to put fresh capital to work next, do not stop here. Broaden your watchlist now with targeted opportunities.

• Target stability and capital protection by reviewing companies screened as 304 resilient stocks with low risk scores that may suit a more cautious approach.
• Hunt for quality at a reasonable price by checking stocks identified in the 257 high quality undervalued stocks that some investors might be overlooking.
• Build a watchlist of potential future standouts by scanning the screener containing 535 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com